HCM Quote, Financials, Valuation and Earnings

Prenetics Global has a net margin of -- compared to HUTCHMED (China)'s net margin of -137.21%. HUTCHMED (China)'s return on equity of -5.49% beat Prenetics Global's return on equity of -23.16%.

HUTCHMED (China) has a consensus price target of $28.11, signalling upside risk potential of 94.23%. On the other hand Prenetics Global has an analysts' consensus of $9.00 which suggests that it could grow by 55.44%. Given that HUTCHMED (China) has higher upside potential than Prenetics Global, analysts believe HUTCHMED (China) is more attractive than Prenetics Global.

HUTCHMED (China) has a beta of 0.781, which suggesting that the stock is 21.86% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.

HUTCHMED (China) quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. HUTCHMED (China)'s net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, HUTCHMED (China)'s price-to-earnings ratio is 30.00x while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 6.00x versus 2.79x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.

Regencell Bioscience Holdings has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of -5.49% beat Regencell Bioscience Holdings's return on equity of --.

HUTCHMED (China) has a consensus price target of $28.11, signalling upside risk potential of 94.23%. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) has higher upside potential than Regencell Bioscience Holdings, analysts believe HUTCHMED (China) is more attractive than Regencell Bioscience Holdings.

HUTCHMED (China) has a beta of 0.781, which suggesting that the stock is 21.86% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.

HUTCHMED (China) quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, HUTCHMED (China)'s price-to-earnings ratio is 30.00x while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 6.00x versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Sino Biopharmaceutical has a net margin of -- compared to HUTCHMED (China)'s net margin of --. HUTCHMED (China)'s return on equity of -5.49% beat Sino Biopharmaceutical's return on equity of 10.53%.

HUTCHMED (China) has a consensus price target of $28.11, signalling upside risk potential of 94.23%. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that HUTCHMED (China) has higher upside potential than Sino Biopharmaceutical, analysts believe HUTCHMED (China) is more attractive than Sino Biopharmaceutical.

HUTCHMED (China) has a beta of 0.781, which suggesting that the stock is 21.86% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.165%.

HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 2.49% to investors and pays a quarterly dividend of $0.00 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out 27.13% of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HUTCHMED (China) quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. HUTCHMED (China)'s net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, HUTCHMED (China)'s price-to-earnings ratio is 30.00x while Sino Biopharmaceutical's PE ratio is 24.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 6.00x versus 1.97x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of -- compared to HUTCHMED (China)'s net margin of 7.83%. HUTCHMED (China)'s return on equity of -5.49% beat Takeda Pharmaceutical's return on equity of 4.01%.

HUTCHMED (China) has a consensus price target of $28.11, signalling upside risk potential of 94.23%. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 21.07%. Given that HUTCHMED (China) has higher upside potential than Takeda Pharmaceutical, analysts believe HUTCHMED (China) is more attractive than Takeda Pharmaceutical.

HUTCHMED (China) has a beta of 0.781, which suggesting that the stock is 21.86% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.

HUTCHMED (China) has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.71% to investors and pays a quarterly dividend of $0.33 per share. HUTCHMED (China) pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend.

HUTCHMED (China) quarterly revenues are --, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. HUTCHMED (China)'s net income of -- is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, HUTCHMED (China)'s price-to-earnings ratio is 30.00x while Takeda Pharmaceutical's PE ratio is 21.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HUTCHMED (China) is 6.00x versus 1.39x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.